Prospective, case-based assessment of sequential therapy with topical fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis

Journal of Drugs in Dermatology

Volumn 10, Issue 4, 2011, Pages 372-378

  Martin, George ^a  

^a Dermatology and Laser Center of Maui   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; FLUOROURACIL; LIQUID NITROGEN; IMMUNOSUPPRESSIVE AGENT; PHOTOSENSITIZING AGENT;

ACTINIC KERATOSIS; AGED; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERTROPHY; MALE; PHOTODYNAMIC THERAPY; SEQUENTIAL ANALYSIS; SUN EXPOSURE; TREATMENT DURATION; TREATMENT RESPONSE; DRUG COMBINATION; PHOTOCHEMOTHERAPY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 80052908860     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gupta AK, Cooper EA, Feldman SR, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis. 2002;70(2 suppl):8-13.
2. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4S-7S.
3. Oppel T, Korting HC. Actinic keratosis: The key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17:67-76. (Pubitemid 38250513)
4. Kalisiak MS, Rao J. Photodynamic therapy for actinic keratoses. Dermatol Clin. 2007;25:15-23. (Pubitemid 44780060)
5. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115:2523-2530.
6. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46:895-904. (Pubitemid 47382273)
7. Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Treatment options in the management of actinic keratosis. Cutis. 2004;74(6 suppl):9-17. (Pubitemid 40125972)
8. Newman MD, Weinberg JM. Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis. 2007;79(4 suppl):18-28.
9. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176-181.
10. Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453-463.
11. Bataille V, Cunningham D, Mansi J, Mortimer P. Inflammation of solar keratoses following systemic 5-fluorouracil. Br J Dermatol. 1996;135:478-480. (Pubitemid 26297852)
12. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 suppl):22-29.
13. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45:96-104. (Pubitemid 32655701)
14. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140:33-40. (Pubitemid 38090268)
15. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629-635.
16. Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol. 2004;3(1 suppl):36S-39S.
17. Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol. 2005;4:161-163.
18. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol. 2009;8:35-39.
19. Gold MH, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol. 2006;5(2 suppl):17-25.
20. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow up. Br J Dermatol. 2007;157(suppl 2):34-40. (Pubitemid 350179628)
21. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467-473. (Pubitemid 40547405)
22. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709-713. (Pubitemid 34023642)
23. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial. J Am Acad Dermatol. 2003;49:83-90. (Pubitemid 36801637)
24. Kligman AL, Thorne EG. Topical therapy of actinic keratoses with tretinoin. In: Marks R, ed. Retinoids in Cutaneous Malignancy. Oxford, UK: Blackwell Scientific Publications;1991:66-73.
25. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol. 1981;4:633-649. (Pubitemid 11037991)
26. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: Mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970;101:132-139.
27. Menter A, Vamvakias G, Jorizzo J. One-week treatment with oncedaily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis. 2008;81:509-516.
28. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: A double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006;5:133-139.
29. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813-816. (Pubitemid 38917849)
30. Carac [package insert]. Bridgewater, NJ: Dermik Laboratories; 2006.
31. Robins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol. 2002;1:25-30.
32. Levulan Kerastick [package insert]. Wilmington, MA: DUSA Pharmaceuticals, Inc.; 2009.
33. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). FDA approved drug products: Levulan. Available at: http://www. accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search. DrugDetails. Accessed June 8, 2010.
34. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol. 1998;68:218-221. (Pubitemid 128472013)
35. Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: Validation in normal mouse skin with topical amino-levulinic acid. Br J Cancer. 2005;92:298-304. (Pubitemid 40343145)
36. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: The VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137:1055-1058. (Pubitemid 32756463)
37. Sachs DL, Kang S, Hammerberg C, et al. Topical fluorouracil for actinic keratoses and photoaging. Arch Dermatol. 2009;145:659-666.
38. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339. (Pubitemid 41757441)
39. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433-440.